78 results
Page 4 of 4
F-1/A
l96eqxudtegib
19 Mar 20
Registration statement (foreign) (amended)
12:21pm
F-1
xm1n9i48
31 Jan 20
Registration statement (foreign)
12:00am
6-K
EX-99.1
x2n9 6e1w87333rl
11 Dec 19
Annual and Special General Meeting of Shareholders
4:38pm
424B5
33yx44 mi6m8
5 Dec 19
Prospectus supplement for primary offering
5:29pm
6-K
EX-99.2
ru73m 786uv7ur8rh05c
7 Nov 19
Therapix Biosciences and Destiny Biosciences Global Corp. Mutually Decide to Discontinue Negotiations on Planned Merger
5:22pm
F-3/A
nd8b5scfvszzm
29 Aug 19
Shelf registration (foreign) (amended)
4:49pm
F-3
u0hqqpcc atgm4
22 Aug 19
Shelf registration (foreign)
5:25pm
6-K
EX-99.1
nv699c5bzovte0pll
31 Jul 19
Therapix Biosciences Announces Canadian Product License Issuance for TheraPEA (CannAmide™), a Non-Opiate Based Pain Management Supplement
4:03pm
424B5
hggqz8p fjvwcjhxdr
1 Apr 19
Prospectus supplement for primary offering
6:57am
6-K
EX-99.1
cr45q5u csfq9c0a
19 Mar 19
Therapix Biosciences Appoints Ambassador Ron Prosor as Executive Advisor
8:04am
6-K
EX-99.1
bpa33
17 Jan 19
Annual General Meeting of Shareholders
4:05pm
6-K
EX-99.1
h6safc7xqmag faef
28 Nov 18
Management’s Discussion and Analysis of Financial Condition and Results of Operations
6:27am
424B2
ufm24vaw
9 Aug 18
Prospectus for primary offering
11:19am
F-3/A
dt0v9
17 Jul 18
Shelf registration (foreign) (amended)
1:29pm
F-3
tfcjey
20 Jun 18
Shelf registration (foreign)
2:38pm
6-K
1pbv9n
17 May 18
Report of Foreign Private Issuer
7:44am
20-F
4qpkig
1 May 17
Annual report (foreign)
12:00am